Trinity Biotech (TRIB) Current Deferred Revenue (2016 - 2020)
Trinity Biotech (TRIB) has disclosed Current Deferred Revenue for 5 consecutive years, with $4.4 million as the latest value for Q4 2020.
- Quarterly Current Deferred Revenue rose 1422.26% to $4.4 million in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $4.4 million through Dec 2020, up 1422.26% year-over-year, with the annual reading at $4.4 million for FY2020, 1422.26% up from the prior year.
- Current Deferred Revenue hit $4.4 million in Q4 2020 for Trinity Biotech, up from $292000.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $4.4 million in Q4 2020 to a low of $224000.0 in Q4 2016.
- Historically, Current Deferred Revenue has averaged $1.1 million across 5 years, with a median of $292000.0 in 2019.
- Biggest five-year swings in Current Deferred Revenue: dropped 6.41% in 2019 and later soared 1422.26% in 2020.
- Year by year, Current Deferred Revenue stood at $224000.0 in 2016, then rose by 24.11% to $278000.0 in 2017, then rose by 12.23% to $312000.0 in 2018, then decreased by 6.41% to $292000.0 in 2019, then skyrocketed by 1422.26% to $4.4 million in 2020.
- Business Quant data shows Current Deferred Revenue for TRIB at $4.4 million in Q4 2020, $292000.0 in Q4 2019, and $312000.0 in Q4 2018.